<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521946</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0495</org_study_id>
    <secondary_id>NCI-2020-05878</secondary_id>
    <secondary_id>2020-0495</secondary_id>
    <nct_id>NCT04521946</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer</brief_title>
  <official_title>A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial investigates the side effects and effectiveness of chemotherapy followed&#xD;
      by a donor (allogeneic) stem cell transplant when given to patients with high grade brain&#xD;
      cancer. Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit&#xD;
      anti-thymocyte globulin, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and&#xD;
      helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow. When the healthy stem cells from a donor are infused into a patient, they may help the&#xD;
      patient's bone marrow make more healthy cells and platelets and may help destroy any&#xD;
      remaining cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess tolerability of allogenic hematopoietic cell transplantation (HCT) among&#xD;
      patients with chemo-responsive high-grade central nervous system (CNS) malignancies as&#xD;
      defined by transplant-related mortality (TRM) at day 30 as well as rate of grade III organ&#xD;
      toxicity or higher (Bearman Regimen-Related Toxicities Scale) attributable to conditioning&#xD;
      occurring within 30 days.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Median time to platelet and neutrophil engraftment. II. Incidence of acute&#xD;
      graft-versus-host disease (aGVHD) by day 100. III. Incidence of chronic GVHD at day 100 and&#xD;
      one year. IV. Rate of grade II organ toxicity through day 100. V. Rate of graft failure&#xD;
      (primary and secondary) through day 100. VI. Rate of infectious complications through day&#xD;
      100. VII. Progression free survival at day 180. VIII. Cumulative incidence of relapse,&#xD;
      overall survival, and progression-free survival at 100 days and 1 year.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive thiotepa intravenously (IV) over 2-4 hours and etoposide IV over 60 minutes&#xD;
      on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate&#xD;
      IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also&#xD;
      receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients&#xD;
      then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning&#xD;
      on day -2 to and mycophenolate mofetil orally (PO) every 8 hours or IV from days 0-40 and&#xD;
      tapered to day 90.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 100, 180, 270 and 360 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">May 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>At day 30</time_frame>
    <description>Will be reported together with the corresponding 95% Bayesian credible interval. Will be estimated using the method of Gooley.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of grade III or higher organ toxicity attributable to conditioning</measure>
    <time_frame>Within 30 days</time_frame>
    <description>Assessed per Bearman Regimen-Related Toxicities Scale. Will be reported together with the corresponding 95% Bayesian credible interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure of platelet and neutrophil engraftment rates</measure>
    <time_frame>Day 100</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host (GVHD) disease</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Will be estimated using the method of Gooley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>At day 100 and 1 year</time_frame>
    <description>Will be estimated using the method of Gooley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade II organ toxicity</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of graft failure (primary and secondary)</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infectious complications</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>At day 100 and 1 year</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At day 100 and 1 year</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At day 100 and 1 year</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anaplastic Ependymoma</condition>
  <condition>Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Central Nervous System Germ Cell Tumor</condition>
  <condition>Choroid Plexus Carcinoma</condition>
  <condition>Intracranial Myeloid Sarcoma</condition>
  <condition>Malignant Brain Neoplasm</condition>
  <condition>Malignant Glioma</condition>
  <condition>Medulloblastoma</condition>
  <condition>Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Anaplastic Ependymoma</condition>
  <condition>Recurrent Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Recurrent Malignant Brain Neoplasm</condition>
  <condition>Recurrent Malignant Glioma</condition>
  <condition>Recurrent Medulloblastoma</condition>
  <condition>Recurrent Primitive Neuroectodermal Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive thiotepa IV over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil PO every 8 hours or IV from days 0-40 and tapered to day 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo HCT</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lapine T-Lymphocyte Immune Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>Anti-Thymocyte Globulin Rabbit</other_name>
    <other_name>Grafalon</other_name>
    <other_name>Rabbit Anti-Human Thymocyte Globulin (RATG)</other_name>
    <other_name>Rabbit Anti-Thymocyte Globulin</other_name>
    <other_name>Rabbit Antithymocyte Globulin</other_name>
    <other_name>Rabbit ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, HCT)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological criteria for any high grade primary or recurrent malignant brain tumor -&#xD;
             medulloblastoma (patients who are ineligible for tandem autologous transplants or who&#xD;
             are at least 3 months post autologous HCT), primitive neuroectodermal tumor (PNET),&#xD;
             atypical teratoid rhabdoid tumor (ATRT), malignant glioma, CNS germ cell tumor,&#xD;
             intracranial sarcomas, choroid plexus carcinoma, anaplastic ependymoma. High grade&#xD;
             tumors defined as those that are grade III or higher based on World Health&#xD;
             Organization (WHO) classification grading system or for medulloblastoma: group 3 and 4&#xD;
             molecular subtypes&#xD;
&#xD;
          -  Patients have to be in at least, a chemo-responsive disease status&#xD;
&#xD;
          -  Available suitable HCT donor&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate (GFR) &gt;= 50 ml/min/1.73m^2, and not&#xD;
             requiring dialysis&#xD;
&#xD;
          -  Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin)&#xD;
             &gt;= 50% predicted. If unable to perform pulmonary function tests, then O2 saturation &gt;=&#xD;
             92% in room air&#xD;
&#xD;
          -  Bilirubin =&lt; 3x upper limit of normal (ULN) (with the exception of isolated&#xD;
             hyperbilirubinemia due to Gilbert's syndrome)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 5x for age&#xD;
&#xD;
          -  DONOR: HCT will be done using stem cell sources in the following order of preference&#xD;
             (and fulfilling minimal cell dose requirements per institutional standards):&#xD;
&#xD;
               -  Matched related donor bone marrow (10 of 10 human leukocyte antigen [HLA] alleles&#xD;
                  [HLA-A, B, C, DR, and DQ]). Matched related donor peripheral blood stem cell&#xD;
                  (PBSC) is allowed only if collection of bone marrow (BM) is not available or&#xD;
                  refused by guardian/donor&#xD;
&#xD;
               -  Matched allogeneic umbilical cord blood: related&#xD;
&#xD;
                    -  High-resolution matching at A,B, DRB1 (minimum 4/6)&#xD;
&#xD;
                    -  Killer-cell immunoglobulin-like receptor (KIR) major histocompatibility&#xD;
                       complex (MHC) class 1 preferential mismatch (minimum 4/6)&#xD;
&#xD;
               -  Matched allogeneic umbilical cord blood: unrelated&#xD;
&#xD;
                    -  High-resolution matching at A,B, DRB1(minimum 4/6)&#xD;
&#xD;
                    -  KIR MHC class 1 preferential mismatch (minimum 4/6)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of histocompatible suitable graft source&#xD;
&#xD;
          -  End-organ failure that precludes the ability to tolerate the transplant procedure,&#xD;
             including conditioning regimen&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Congenital heart disease resulting in congestive heart failure&#xD;
&#xD;
          -  Ventilatory failure: requires invasive mechanical ventilation&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infections&#xD;
&#xD;
          -  A female of reproductive potential who is pregnant, planning to become pregnant during&#xD;
             the study, or is nursing a child&#xD;
&#xD;
          -  Any patient who does not fulfill inclusion criteria listed above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris M Mahadeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris M. Mahadeo</last_name>
      <phone>713-792-6610</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Kris M. Mahadeo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Sarcoma, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

